Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association (2010) Circulation 121: 833-40 Urological cancer: walking the tightrope of survival and quality of life with ADT. Resnick MJ (2013) Nat Rev Clin Oncol 10: 307-8 A luteinizing hormone-releasing hormone agonist decreases biological activity and modifies chromatographic behavior of luteinizing hormone in man. Evans RM, Doelle GC, Lindner J, Bradley V, Rabin D (1984) J Clin Invest 73: 262-6 Ovarian steroids differentially modulate the gene expression of gonadotropin-releasing hormone neuronal subtypes in the ovariectomized cynomolgus monkey. Krajewski SJ, Abel TW, Voytko ML, Rance NE (2003) J Clin Endocrinol Metab 88: 655-62 Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men. Pavlou SN, Wakefield G, Schlechter NL, Lindner J, Souza KH, Kamilaris TC, Konidaris S, Rivier JE, Vale WW, Toglia M (1989) J Clin Endocrinol Metab 68: 446-54 Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration. Pavlou SN, Dahl KD, Wakefield G, Rivier J, Vale W, Hsueh AJ, Lindner J (1988) J Clin Endocrinol Metab 66: 1005-9 Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. Pavlou SN, Brewer K, Farley MG, Lindner J, Bastias MC, Rogers BJ, Swift LL, Rivier JE, Vale WW, Conn PM (1991) J Clin Endocrinol Metab 73: 1360-9 Regulation of pituitary glycoprotein alpha-subunit secretion after administration of a luteinizing hormone-releasing hormone antagonist in normal men. Lindner J, Rivier JE, Vale WW, Pavlou SN (1990) J Clin Endocrinol Metab 70: 1219-24 Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men. Pavlou SN, Veldhuis JD, Lindner J, Souza KH, Urban RJ, Rivier JE, Vale WW, Stallard DJ (1990) J Clin Endocrinol Metab 70: 1472-8 Characterization of human anti-luteinizing hormone-releasing hormone (LRH) antibodies in the serum of a patient with isolated gonadotropin deficiency treated with synthetic LRH. Lindner J, McNeil LW, Marney S, Conway M, Rivier J, Vale W, Rabin D (1981) J Clin Endocrinol Metab 52: 267-70 Estradiol-17 beta and mu-opioid peptides rapidly hyperpolarize GnRH neurons: a cellular mechanism of negative feedback? Lagrange AH, Rønnekleiv OK, Kelly MJ (1995) Endocrinology 136: 2341-4 Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM (2007) J Urol 177: 1307-12 The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M (2005) J Urol 174: 547-52; discussion 552 Cyclical expression of GnRH and GnRH receptor mRNA in lymphoid organs. Jacobson JD, Crofford LJ, Sun L, Wilder RL (1998) Neuroendocrinology 67: 117-25 Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE (2012) BJU Int 110: E721-6 Prostate cancer and bone metastases: medical treatment. Clark PE, Torti FM (2003) Clin Orthop Relat Res : S148-57 Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Beer TM, Schellhammer PF, Corman JM, Glodé LM, Hall SJ, Whitmore JB, Frohlich MW, Penson DF (2013) Urology 82: 410-5 Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Tsai HT, Penson DF, Makambi KH, Lynch JH, Van Den Eeden SK, Potosky AL (2013) Urology 82: 327-33 Dissociation of LH and FSH Responses to LHRH during estrogen therapy of patients with ovarian failure. Linde R, Lindner J, Lorber D, Rabin D (1982) Horm Metab Res 14: 154-6
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.